Latest From Incyte Corp.
A group of early-stage investigational cancer, myelofibrosis and immune-oncology products have been tagged by AbbVie as potential therapies of interest longer term.
Trulicity, Taltz grew in the first quarter, but below analyst consensus estimates. Company points to price decreases as holding down growth.
The number of US drug approvals in 2018 was striking, but most of the novel products launched last year are for rare diseases or niche cancers, meaning commercial success may be in the eye of the beholder.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Incyte Pharmaceuticals Inc.
- Incyte Genomics Inc.
- North America
- Parent & Subsidiaries
- Incyte Corp.
- Senior Management
Hervé A Hoppenot, MD, Pres. & CEO
David W Gryska, EVP, CFO
Dashyant Dhanak , PhD, EVP, CSO
Vijay Iyengar, MD, EVP, Global Strategy & Corp. Dev.
Steven H Stein, MD, EVP, CMO
- Contact Info
Phone: (302) 498-6700
1801 Augustine Cut-Off
Wilmington, DE 19803
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.